Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Japanese researchers describe compounds for lipoprotein disorders

Feb. 3, 1997

FDA approves Teva drug

Jan. 31, 1997

FDA approves antidiabetic drug within 6 months of filing

Jan. 31, 1997

Biotech launches Diab II

Jan. 31, 1997

Shaman describes antidiabetic agents from natural source

Jan. 31, 1997

Takeda researches follow-up compounds to leuprorelin

Jan. 31, 1997

Mixed CCK-A agonist/CCK-B antagonist from Glaxo Wellcome

Jan. 30, 1997

NutraGenics changes name, receives patent coverage for proprietary technology

Jan. 30, 1997

Pfizer reveals agents for hypercholesterolemia, atherosclerosis

Jan. 30, 1997

Antisense compound targeting cholesterol reported

Jan. 29, 1997

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...